contact us
Cambridge, Mass.-based Biogen and Tokyo, Japan-based Eisai announced results from an analysis of their ongoing long-term extension (LTE) Phase Ib trial of aducanumab for Alzheimer’s disease.
Do Not Allow Advertisers to Use My Personal information
